Chemotherapy for esthesioneuroblastomas.
Esthesioneuroblastoma can be regarded as a chemosensitive tumor based on multiple reports of response to treatment. Neoadjuvant therapy is seldom curative, however, and may be of no benefit in some patients. Individuals who respond to preoperative therapy have a greater chance of long-term disease-free survival. Platinum-based therapy has been the mainstay of treatment. Toxicity has been mild, and treatment failures have been treated with postoperative chemotherapy with or without bone marrow transplantation. Given the small number of cases of esthesioneuroblastoma diagnosed annually, it is unlikely that any consensus on this issue is forthcoming. Either post- or presurgical treatment of advanced stage or recurrent disease has become the standard of care, however.
Sheehan
J M
JM
Department of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Sheehan
J P
JP
Jane
J A
JA
Polin
R S
RS
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D019292:Skull Base Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
D000970:Antineoplastic Agents